Medtronic (NYSE: MDT) announced positive primary and secondary outcomes for its VenaSeal spectrum venous leg ulcer (VLU) ...

Vivasure hope to find room in a competitive market with its surtureless implant that is absorbed 180 days after vessel ...

Medtronic announced the primary and secondary outcomes of the VenaSeal Spectrum Venous Leg Ulcer study. According to the ...

Sadly, due to a decline in reimbursements, combined with continuing increases in supplies and overhead, we are announcing the ...

Per UPMC’s website, PFO closure surgery is effective for reducing stroke ... instead relying on a catheter that is threaded through a vein in the groin and guided to the heart.

The biggest names in cardiac care gathered in San Diego for the Heart Rhythm Society (HRS) 2025 Annual Meeting.

Learn more about whether LeMaitre Vascular, Inc. or PROCEPT BioRobotics Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether LeMaitre Vascular, Inc. or Lantheus Holdings, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

A case-based discussion navigates the decision-making process for a patient with chronic limb-threatening ischemia with poor ...